Bulletin of the Korean Chemical Society · 2018 · 24 citations · 13 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyMolecular OncologyOncogenesAllosteric Drug DesignAllosteric RegulationEnzyme InhibitionTyrosine Kinase InhibitorsAllosteric InhibitionAllosteric Inhibition MechanismsEgfr Inhibition
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
13
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al. · New England Journal of Medicine · 2010 · 5.6K citations
Medicine, Oncology, Pharmacology +13
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text
Medicine, Oncology, Pharmacology +16
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia, Cai‐Hong Yun, Eunyoung Park et al. · Nature · 2016 · 879 citations · Full text
Medicine, Oncology, Pharmacology +11
Matthew J. Niederst, Haichuan Hu, Hillary E. Mulvey et al. · Clinical Cancer Research · 2015 · 548 citations · Full text
Medicine, Oncology, Pharmacology +14